NCT06727344 Conservative Treatment With Blood Flow Restriction in Patients With Total ACL Rupture. "Randomized Clinical Trial"
| NCT ID | NCT06727344 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European University Cyprus |
| Condition | ACL |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2025-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-02-01 with a primary completion date of 2025-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomised clinical trial is to evaluate the effects of exercise with blood flow restriction (BFR) in patients with a complete anterior cruciate ligament (ACL) rupture. The main questions it aims to answer are: 1. Does blood flow restriction adds any additional benefits to conservative treatment of the ACL? 2. Does bracing promotes spontaneous healing to the ACL Researchers will compare bracing and BFR to bracing and sham BFR to see if the intervention provides any additional benefits to the conservative management of this injury. Participants will: 1. Use a knee brace for 6 weeks with adjustments according to protocol 2. Follow and identical exercise plan with either BFR (intervention group) or BFR sham (control group) 3. Follow a home based exercise program.
Eligibility Criteria
Inclusion Criteria: * MRI-confirmed complete rupture of ACL. Ability to communicate and read fluently in Greek and be willing to keep their leg immobilised for the required period based on the study protocol. Exclusion Criteria: * Heart disease, overweight, diabetes, pregnancy, thrombophilia, atrial fibrillation, heart failure, cancer, use of drugs that may increase blood clotting, use of hormones or contraceptives, any reason for not using BFR e.g., an open wound or serious skin problems and/or allergies to the cuff material.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06727344 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying ACL. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06727344 currently recruiting?
Yes, NCT06727344 is actively recruiting participants. Contact the research team at alexpitsillides@gmail.com for enrollment information.
Where is the NCT06727344 trial being conducted?
This trial is being conducted at Nicosia, Cyprus, Nicosia, Cyprus.
Who is sponsoring the NCT06727344 clinical trial?
NCT06727344 is sponsored by European University Cyprus. The trial plans to enroll 20 participants.